Home > News > APP Announces Positive Results of Intra-Arterial ABI-007
June 4th, 2003
APP Announces Positive Results of Intra-Arterial ABI-007
At the American Society of Clinical Oncology annual meeting held in Chicago, Illinois, American Pharmaceutical Partners, Inc. said that investigators from the Insituto dei Tumori in Milan, Italy, reported on their experience in 108 patients receiving high dose ABI-007, a novel cremophor-free protein engineered nanoparticle paclitaxel, by the intra-arterial route.
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014
Unraveling the light of fireflies December 17th, 2014
First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014
Nanomedicine expert joins Rice faculty: Gang Bao combines genetic, nano and imaging techniques to fight disease December 17th, 2014